Matches in SemOpenAlex for { <https://semopenalex.org/work/W4309016311> ?p ?o ?g. }
Showing items 1 to 74 of
74
with 100 items per page.
- W4309016311 endingPage "vii64" @default.
- W4309016311 startingPage "vii64" @default.
- W4309016311 abstract "Abstract BACKGROUND The glioblastoma (GBM) tumor microenvironment (TME) is characterized by a paucity of effector T cells and massive infiltration of immunosuppressive tumor-associated macrophages (TAMs). Inhibition of the interleukin-6 receptor (IL6R) has been demonstrated in preclinical models to repolarize TAMs toward an immunostimulatory phenotype, rendering GBM more susceptible to PD-1/PD-L1 inhibition. Additional preclinical data suggest that fractionated stereotactic radiotherapy (FSRT) can stimulate the release and presentation of tumor-specific antigens, acting as an in-situ vaccine and potentially converting a “cold” TME to a T cell-inflamed state. We designed a safety run-in and phase II study to evaluate the efficacy, safety, and impact on the TME of the combination of IL6R inhibition (tocilizumab), PD-L1 inhibition (atezolizumab), and FSRT in patients with recurrent GBM (rGBM). METHODS NRG-BN010 (NCT04729959) is open to enrollment for adults with rGBM following prior radiotherapy and has 3 components: a safety run-in to determine the recommended phase II dose (RP2D) of the treatment regimen, a phase II single-arm nonsurgical cohort to assess efficacy of the treatment regimen at the RP2D, and a window-of-opportunity surgical cohort. Once the safety run-in (n=12, 3 + 3 design) has determined the RP2D, the phase II and surgical cohorts will open. Phase II patients (n=25, Simon 2-stage design, primary endpoint objective radiographic response) receive an initial pre-FSRT cycle of tocilizumab (plus atezolizumab if included in the RP2D). Within 3-7 days later, the patient receives FSRT (8 Gy x 3 fx), followed by resumption of systemic therapy. Surgical cohort patients (n=16, 1:1 randomization) receive a neoadjuvant cycle of atezolizumab with (n=8) vs. without (n=8) tocilizumab, then FSRT 3-7 days later, then surgical resection 7-14 days after FSRT. Post-operatively, all patients resume systemic therapy at the RP2D. Fresh tumor tissues will be subjected to deep immune profiling to understand the impact of tocilizumab on TAMs in the GBM TME." @default.
- W4309016311 created "2022-11-20" @default.
- W4309016311 creator A5004472974 @default.
- W4309016311 creator A5006742893 @default.
- W4309016311 creator A5017206877 @default.
- W4309016311 creator A5034125535 @default.
- W4309016311 creator A5038585908 @default.
- W4309016311 creator A5044802659 @default.
- W4309016311 creator A5057536092 @default.
- W4309016311 creator A5060738532 @default.
- W4309016311 creator A5087754052 @default.
- W4309016311 date "2022-11-01" @default.
- W4309016311 modified "2023-10-08" @default.
- W4309016311 title "CTIM-21. NRG-BN010: A SAFETY RUN-IN AND PHASE II STUDY EVALUATING THE COMBINATION OF TOCILIZUMAB, ATEZOLIZUMAB, AND FRACTIONATED STEREOTACTIC RADIOTHERAPY IN RECURRENT GLIOBLASTOMA – TRIAL IN PROGRESS" @default.
- W4309016311 doi "https://doi.org/10.1093/neuonc/noac209.253" @default.
- W4309016311 hasPublicationYear "2022" @default.
- W4309016311 type Work @default.
- W4309016311 citedByCount "0" @default.
- W4309016311 crossrefType "journal-article" @default.
- W4309016311 hasAuthorship W4309016311A5004472974 @default.
- W4309016311 hasAuthorship W4309016311A5006742893 @default.
- W4309016311 hasAuthorship W4309016311A5017206877 @default.
- W4309016311 hasAuthorship W4309016311A5034125535 @default.
- W4309016311 hasAuthorship W4309016311A5038585908 @default.
- W4309016311 hasAuthorship W4309016311A5044802659 @default.
- W4309016311 hasAuthorship W4309016311A5057536092 @default.
- W4309016311 hasAuthorship W4309016311A5060738532 @default.
- W4309016311 hasAuthorship W4309016311A5087754052 @default.
- W4309016311 hasConcept C121608353 @default.
- W4309016311 hasConcept C126322002 @default.
- W4309016311 hasConcept C143998085 @default.
- W4309016311 hasConcept C203092338 @default.
- W4309016311 hasConcept C2775949291 @default.
- W4309016311 hasConcept C2777178219 @default.
- W4309016311 hasConcept C2777575956 @default.
- W4309016311 hasConcept C2777701055 @default.
- W4309016311 hasConcept C2780030458 @default.
- W4309016311 hasConcept C2781413609 @default.
- W4309016311 hasConcept C31760486 @default.
- W4309016311 hasConcept C535046627 @default.
- W4309016311 hasConcept C71924100 @default.
- W4309016311 hasConceptScore W4309016311C121608353 @default.
- W4309016311 hasConceptScore W4309016311C126322002 @default.
- W4309016311 hasConceptScore W4309016311C143998085 @default.
- W4309016311 hasConceptScore W4309016311C203092338 @default.
- W4309016311 hasConceptScore W4309016311C2775949291 @default.
- W4309016311 hasConceptScore W4309016311C2777178219 @default.
- W4309016311 hasConceptScore W4309016311C2777575956 @default.
- W4309016311 hasConceptScore W4309016311C2777701055 @default.
- W4309016311 hasConceptScore W4309016311C2780030458 @default.
- W4309016311 hasConceptScore W4309016311C2781413609 @default.
- W4309016311 hasConceptScore W4309016311C31760486 @default.
- W4309016311 hasConceptScore W4309016311C535046627 @default.
- W4309016311 hasConceptScore W4309016311C71924100 @default.
- W4309016311 hasIssue "Supplement_7" @default.
- W4309016311 hasLocation W43090163111 @default.
- W4309016311 hasOpenAccess W4309016311 @default.
- W4309016311 hasPrimaryLocation W43090163111 @default.
- W4309016311 hasRelatedWork W1608269846 @default.
- W4309016311 hasRelatedWork W2484703144 @default.
- W4309016311 hasRelatedWork W2604148568 @default.
- W4309016311 hasRelatedWork W2790303407 @default.
- W4309016311 hasRelatedWork W3088074323 @default.
- W4309016311 hasRelatedWork W3216431241 @default.
- W4309016311 hasRelatedWork W4212796756 @default.
- W4309016311 hasRelatedWork W4221031788 @default.
- W4309016311 hasRelatedWork W4221038606 @default.
- W4309016311 hasRelatedWork W4291555108 @default.
- W4309016311 hasVolume "24" @default.
- W4309016311 isParatext "false" @default.
- W4309016311 isRetracted "false" @default.
- W4309016311 workType "article" @default.